Managed Care - July 2008 - (Page H2) SELF-STUDY CONTINUING EDUCATION ACTIVITY Hematologic Cancer as a Chronic Disease A statement of credit is offered to healthcare professionals who read pages 3 through 19 of this publication and submit the assessment and evaluation form on page 20. CME and CPE credit are offered. Estimated time to complete this activity is 2 hours. A statement of credit will be awarded upon successful completion of assessment questions (70 percent or better). If a score of 70 percent or better is not achieved, no credit will be awarded, and the registrant will be so notified. There is no fee for this activity. Target audience This program is targeted to medical directors, clinical and managed care pharmacists, and other health care decision makers in MCOs, health systems, academia, and industry. Overview/needs assessment Innovative approaches to cancer treatment are profoundly changing the management of many types of cancer. A host of new therapies with novel mechanisms of action are improving survival and are reducing morbidity, thereby shifting certain cancers into the chronic disease category. With these important advances in cancer care, MCOs will need to develop tools, processes, and analytics to manage these patient populations in optimal fashion. This publication will focus on practical issues and challenges in the management of hematologic malignancies, including multiple myeloma and myelodysplastic syndromes. This program also will provide updates on treatment options that can be integrated into the treatment of patients with various hematologic malignancies. Another important focus of this educational program will be CMS guidance with respect to clinical management of cancer patients and Medicare reimbursement policies in the arena of hematologic malignancies. Educational objectives After reading this publication, participants will be able to: • Review clinical advances, including current and emerging therapeutics, and the epidemiology of hematologic cancers, specifically multiple myeloma and myelodysplastic syndromes. • Discuss the components of the Medicare policy in the area of oncology. • Assess best practices for cancer management within a managed care setting and the impact of the managed care pharmacist on patient care. Accreditation and designation This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the sponsorship of The Chatham Institute. The Chatham Institute is accredited by the ACCME to provide continuing medical education for physicians. The Chatham Institute designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits.TM Physicians should claim credit commensurate with the extent of their participation in the activity. The Chatham Institute is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 2.0 contact hours (0.2 CEU) of continuing education for pharmacists. ACPE Universal Program Number (UPN): 812-000-08-017-H01-P Release Date: July 15, 2008 Expiration Date: July 15, 2009 Medium: Journal supplement Planning committee members Steven Coutré, MD; Joseph M. Tuscano, MD; Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD; Ronnie J. DePue, RPh; Chad Bertling, CE director, and Steven R. Peskin, MD, MBA, medical director, The Chatham Institute; Amy Krajacic, editor. Conflict-of-interest policy and disclosures of significant relationships It is the policy of The Chatham Institute to ensure balance, independence, objectivity, and scientific rigor in all of its educational programs. The Chatham Institute requires the disclosure of any significant financial interest or any other relationship a facility member may have with the manufacturer(s) of any commercial product(s) or device(s). Further, faculty members are required to disclose discussion of any offlabel uses in their presentation. Any faculty members not complying with the disclosure policy are not permitted to participate in the educational activity. Steven Coutré, MD, makes references to unlabeled/unapproved uses of lenalidomide in his article. All program content has been peer reviewed for balance and any potential bias. Peer reviewers of this program have no real or apparent conflicts of interest to report with respect to the content of this publication. The process to resolve conflicts of interest aims to ensure that financial relationships with commercial interests and resultant loyalties do not supersede the public interest in the design and delivery of continuing medical activities for the profession. The faculty of this program and the editorial staff of this monograph have disclosed the following: Steven Coutré, MD: Honoraria from Novartis, Celgene, and Bristol-Myers Squibb, and consulting fees from Celgene. Joseph M. Tuscano, MD: Honoraria from Amgen, Celgene, and Genentech. Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD: Grant/research support from the American Society of Consultant Pharmacists, sanofi-aventis, Amgen, and Merck; and consulting fees from Celgene, NewCourtland Elder Services, Baxter Healthcare, Eisai, Pfizer, sanofi-aventis, Sepracor, Amgen, Merck, and Johnson & Johnson. He also serves on the speaker’s bureau for Pfizer, Ortho McNeil, Abbott, GlaxoSmithKline, AstraZeneca, Forest Laboratories, Amgen, Merck, Daiichi Sankyo, Par, Eisai, and Schering-Plough, and the advisory boards for Pfizer, Eisai, Janssen, Solvay, Takeda, and Genentech. Ronnie J. DePue, RPh; Steven R. Peskin, MD, MBA; Chad Bertling, CE director; and Amy Krajacic, editor: No real or apparent conflicts of interest to report with respect to the content of this publication. Program sponsorship and support This activity is sponsored by The Chatham Institute, and is supported by an educational grant by Celgene Corp. 2 MANAGED CARE / SUPPLEMENT
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.